Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as isophosphoramide mustard-tris, Zymafos (TM)
palifosfamide-tris · 2 trials · 9 indications
To assess the effect of single-agent palifosfamide-tris on QTc intervals.
To assess the pharmacokinetic profile of single-agent palifosfamide-tris.
Adverse events, vital signs, physical examination, laboratory data and concomitant medications
| Arm | Type | Description |
|---|---|---|
| Single Arm | OTHER | Single Arm, non-blinded, non-randomized |
| PaCE | EXPERIMENTAL | Palifosfamide, Carboplatin and Etoposide |
| Name | Type | Description |
|---|---|---|
| palifosfamide-tris | DRUG | palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle) |
| Normal Saline | DRUG | 0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1 |
Inclusion criteria: 1. Male or female subjects, age ≥ 18 years, who have provided written informed consent prior to completing any study specific procedure. 2. Histologically or cytologically confirmed solid tumor that has progressed following available standard therapies or for which no standard t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
Palifosfamide-tris is an investigational small molecule oncology drug being developed by Alaunos Therapeutics, Inc. It has been studied in Phase 1 clinical trials in patients with advanced solid tumors and other malignancies. It is not an approved therapy and remains in clinical development.
Palifosfamide-tris has been studied in patients with advanced solid tumors and malignancies, including non small cell lung cancer, small cell lung cancer, testicular cancer, thymoma, ovarian cancer, and osteosarcoma. All of this testing has been in Phase 1 trials, so the drug is investigational and has no approved indication.
Palifosfamide-tris is being developed by Alaunos Therapeutics, Inc., which trades under the ticker TCRT. The company has sponsored Phase 1 studies of the small molecule in advanced solid tumors and in combination with chemotherapy in patients with various malignancies.
Palifosfamide-tris is in Phase 1 clinical development. Its trials in advanced solid tumors and malignancies have been completed, and no active trials are currently listed. The drug is investigational and has not been approved by the FDA for any indication.
Palifosfamide-tris has been evaluated in two completed Phase 1 trials. NCT01340547 studied single-agent palifosfamide-tris for its effect on QTc, pharmacokinetics, safety, and preliminary efficacy in 24 patients with advanced solid tumors. NCT01242072 studied intravenous palifosfamide-tris with etoposide and carboplatin in 22 patients with malignancies.